Corcept Therapeutics (CORT) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 32.4% versus a loss of 12.5%. Over five years, CORT leads with a +496.8% price change compared with -7.1% for RDY. Corcept Therapeutics is the larger company by market cap ($12.93 billion vs $10.22 billion), about 1.3 times the size, while Dr. Reddy's Laboratories is growing revenue faster (+13.8% vs +12.8%).
On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (19.0x vs 27.2x for Corcept Therapeutics). Dr. Reddy's Laboratories pays a dividend yielding 65.20%, while Corcept Therapeutics does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus 13.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | RDY |
|---|---|---|
| Share price | $119.60 | $12.27 |
| Market cap | $12.93B | $10.22B |
| 1-day change | +0.03% | -1.76% |
| YTD return | +243.68% | -12.61% |
| 1-year return | +32.42% | -12.54% |
| 5-year return | +496.81% | -7.06% |
| P/E ratio (TTM) | 265.78 | 27.89 |
| Forward P/E | 27.17 | 19.04 |
| EPS (TTM) | $0.45 | $0.44 |
| Dividend yield | 0.00% | 65.20% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $761.41M | $3.81B |
| Revenue growth (YoY) | +12.79% | +13.76% |
| Net income (latest FY) | $99.65M | $663.00M |
| Gross margin | 98.30% | 58.51% |
| Operating margin | 5.88% | 22.09% |
| Net margin | 13.09% | 17.40% |
| 52-week high | $126.38 | $15.67 |
| 52-week low | $28.66 | $11.36 |
| Distance from 52-week high | -5.36% | -21.70% |
| Analyst consensus | buy | none |
| Avg. price target upside | +17.89% | +7.74% |
| Average volume | 1.31M | 2.92M |
| Shares outstanding | 108.10M | 832.99M |
| Employees | 730 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed RDY by 45.0 percentage points over the past year.
- Corcept Therapeutics trades at a higher earnings multiple (265.8x vs 27.9x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.20% vs 0.00%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
CORT vs RDY FAQ
Which is bigger, Corcept Therapeutics or Dr. Reddy's Laboratories?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $12.93B compared with $10.22B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, CORT or RDY?
CORT returned +32.42% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CORT or RDY?
RDY has the lower trailing P/E at 27.9, versus 265.8 for CORT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Corcept Therapeutics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.20%, while Corcept Therapeutics does not currently pay a regular dividend.
Are Corcept Therapeutics and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.